Sesen Bio (SESN) Earns Daily Media Sentiment Rating of 0.21
Media headlines about Sesen Bio (NASDAQ:SESN) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sesen Bio earned a news impact score of 0.21 on Accern’s scale. Accern also gave news coverage about the company an impact score of 48.3909326888201 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Brokerages Anticipate Sesen Bio Inc (SESN) to Post ($0.12) Earnings Per Share (americanbankingnews.com)
- Sesen Bio’s Vicinium Fast Track’d for bladder cancer; shares up 12% premarket (seekingalpha.com)
- Brokerages Expect Sesen Bio Inc (SESN) Will Post Earnings of -$0.12 Per Share (americanbankingnews.com)
- Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer (finance.yahoo.com)
- New chief at Sesen Bio; shares up 3% after hours (seekingalpha.com)
Sesen Bio traded up $0.06, reaching $1.79, during trading on Friday, according to Marketbeat Ratings. 624,578 shares of the company’s stock were exchanged, compared to its average volume of 637,358. Sesen Bio has a fifty-two week low of $0.62 and a fifty-two week high of $3.50. The firm has a market capitalization of $83.71 million, a PE ratio of -1.61 and a beta of 2.49.
A number of brokerages have commented on SESN. Zacks Investment Research lowered Sesen Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, July 25th. HC Wainwright raised their price objective on Sesen Bio to $3.50 and gave the stock an “in-line” rating in a research report on Tuesday, May 22nd. Canaccord Genuity began coverage on Sesen Bio in a research report on Monday, July 9th. They set a “buy” rating for the company. Finally, Jefferies Financial Group began coverage on Sesen Bio in a research report on Monday, July 23rd. They set a “buy” rating and a $4.00 price objective for the company.
Sesen Bio Company Profile
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.
Further Reading: Market Capitalization
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.